What Challenges Exist in Targeting Bcl-2 Family Proteins?
While targeting Bcl-2 family proteins holds promise, there are challenges. Cancer cells often develop resistance to BH3 mimetics through upregulation of other anti-apoptotic family members like Mcl-1. Combination therapies that target multiple Bcl-2 family members simultaneously are being explored to overcome resistance and improve therapeutic outcomes.